Clinical Trial

Speech-based Assessment of Relapse Risk in People With Psychosis

Study acronym: TRUSTING-WP4
Recruiting
View on ClinicalTrials.gov →
Summary
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis. Over 12 months, patients at risk of relapse and healthy controls will provide weekly speech recordings and self-report data for automated analysis. Risk scores will be stored but not shared with treating clinicians. Independent clinical evaluations ensure data quality and validation. The study lays the foundation for future Clinical Decision Support System (CDSS) research and explores novel speech markers for relapse prediction while minimizing participant burden.
Trial Details
NCT Number NCT07397975
Lead Sponsor Philipp Homan
Conditions Psychotic Disorder
Enrollment 360 participants
Start Date 2026-01-29
Primary Completion 2029-01-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09